The aim of this study was to treat carcinoembryonic antigen (CEA)-expressing pancreatic carcinoma cells with tumour necrosis factor alpha (TNFa) and simultaneous radiation therapy (RT), using a bispecific antibody (BAb) anti-TNFa/anti-CEA. TNFa used alone produced a dose-dependent inhibition of the clonogenic capacity of the cultured cells. Flow cytometry analysis of cell cycle progression confirmed the accumulation of cells in G 1 phase after exposure to TNFa. When TNFa was added 12 h before RT, the surviving fraction at 2 Gy was 60% lower than that obtained with irradiation alone (0.29 vs 0.73, respectively, Po0.00001). In combination treatment, cell cycle analysis demonstrated that TNFa reduced the number of cells in radiation-induced G 2 arrest, blocked irreversibly the cells in G 1 phase, and showed an additive decrease of the number of cells in S phase. In mice, RT as a single agent slowed tumour progression as compared with the control group (Po0.00001). BAb þ TNFa þ RT combination enhanced the delay for the tumour to reach 1500 mm 3 as compared with RT alone or with RT þ TNFa (P ¼ 0.0011). Median delays were 90, 93, and 142 days for RT alone, RT þ TNFa, and RT þ BAb þ TNFa groups, respectively. These results suggest that TNFa in combination with BAb and RT may be beneficial for the treatment of pancreatic cancer in locally advanced or adjuvant settings.
Adenocarcinoma of the pancreas remains one of the most difficult malignancies to treat. The incidence has steadily increased over the past four decades (Gudjonsson, 1987) , and its prognosis is still dismal, despite tremendous efforts in early diagnosis and therapy. The 5-year survival rate is less than 5% with a complete surgical resection (Gudjonsson, 1987) , ranking this cancer fourth among the leading causes of cancer death (Parker et al, 1996) . Unfortunately, at the time of diagnosis, the majority of patients (80 -90%) have locally or metastatic inoperable tumours. Radiation therapy (RT) alone or in combination with chemotherapy showed modest efficacy in local control and palliation (Andre et al, 2000; Kornek et al, 2000; Azria et al, 2002) . Despite these intensive efforts to improve the efficacy of conventional therapy, no satisfactory progress in dealing with this cancer has been made. Accordingly, new treatment modalities are required for this tumour.
Current interest has focused on biological response modifiers as antineoplastic agents. Among them, tumour necrosis factor alpha (TNFa) was originally identified as a tumoricidal protein effecting haemorrhagic necrosis of transplanted solid tumours in mice (Carswell et al, 1975) . It is a multipotent cytokine produced mainly by activated macrophages with the ability to mediate cytotoxicity both in vitro (Sugarman et al, 1985) and in vivo (Carswell et al, 1975; Helson et al, 1979) . TNFa usually does not kill untransformed cells (Sugarman et al, 1985) but shows an antiproliferative effect on certain tumour cells in vitro by still undefined mechanisms. Recently, Ruegg et al (1998) reported evidence for the involvement of endothelial cell integrin avb3 in the disruption of the tumour vasculature induced by the combination of TNFa and IFNg.
Several in vitro clonogenic assays suggest that an additive or a supra-additive interaction may occur between TNFa and ionising radiation (Hallahan et al, 1990; Gridley et al, 1994a; Azria et al, 2003a) as well as an enhancement of the antitumour effect of radiation in some murine and human tumours in vivo (Sersa et al, 1988; Nishiguchi et al, 1990; Gridley et al, 1997; Azria et al, 2003a) . The oxidative damage produced by TNFa (Zimmerman et al, 1989) may enhance cellular damage produced by ionising radiation. In addition, TNFa and radiation can induce apoptosis in target cells (Yamada and Ohyama, 1988; Langley et al, 1993) even if cells are normally highly resistant to the induction of radiation-induced apoptosis (Kimura et al, 1999) .
In different clinical trials using systemic injection of TNFa, the results have been disappointing mainly because patients were found to have significantly lower maximum tolerated doses (Abbruzzese et al, 1989; Moritz et al, 1989) as compared with mice (Asher et al, 1987; Havell et al, 1988) . These limited results were probably due to the short circulatory half-life of TNFa and its severe systemic side effects. Studies involving regional (Lienard et al, 1992; Mavligit et al, 1992; Lejeune et al, 1998) or intratumoral (van der Schelling et al, 1992) injection of TNFa have demonstrated its potential for cancer therapy, but only when a high enough therapeutic concentration of TNFa was obtained in the tumour with a nontoxic systemic concentration. To overcome this limitation, we used previously a bispecific antibody (BAb) directed against carcinoembryonic antigen (CEA) and TNFa to target this cytokine in human CEA-expressing colorectal carcinoma treated simultaneously with RT (Azria et al, 2003a) .
In the present study, we report the results of clonogenic tests of pancreatic (BxPC-3) cell survival, which confirm a superiority of the radiation-TNFa combination as compared with radiation alone. We show here a nonreversible cell cycle arrest of these cells treated by TNFa alone or in combination with ionising radiation. Using nude mice-bearing BxPC-3 xenografts, we showed a significant enhanced tumour growth delay when the BAb þ TNFa þ RT combination was used as compared with RT alone and with RT þ TNFa.
MATERIALS AND METHODS

Cell line and cell culture
The CEA-expressing human pancreatic carcinoma BxPC-3 cell line (Tan et al, 1986) was obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were cultured in RPMI-1640 medium (Gibco Laboratories, France) supplemented with 10% heat-inactivated fetal calf serum (Gibco Laboratories, France), 300 mg ml À1 glutamine, 0.25 mg ml À1 fungizone, 100 mg ml À1 streptomycin, and 100 U ml À1 penicillin G. These cells were adherent and grew as monolayers at 371C in a humidified 5% CO 2 incubator. The BxPC-3 cells were harvested with 0.5 g l À1 trypsin (Gibco Laboratories, France) and 0.2 g l À1 EDTA (Gibco Laboratories, France) for 3 min. Cultures were checked for the absence of mycoplasma every month.
TNFa and BAb
Recombinant human TNFa, kindly provided by Dr GR Adolf (Boehringer Ingelheim, Wien, Austria), was prepared by expression of a synthetic gene in Escherichia coli. The specific activity of TNFa, determined in the presence of actinomycin D, was 5 Â 10 7 U mg À1 protein as determined by cytolysis of murine L929 cells. TNFa (at a concentration of 2.5 mg ml À1 ) was stored at -801C until use.
BAb was constructed as previously described (Robert et al, 1996) from the anti-CEA MAb 35A7 (Haskell et al, 1983) and the MAb tnf18 kindly provided by Dr M Brockhaus (Hoffmann-La Roche AG, Basel, Switzerland).
Radiation protocols
Cells were plated in 10 ml RPMI (to ensure homogeneous energy deposition within each dish) using 60-mm Petri dishes and irradiated with a cobalt-60 ( 60 Co) source (g-irradiation, ELITE 100, Theratronics) in the Radiation Department. The radiation was delivered as a single dose ranging from 2 to 10 Gy in an 11 cm Â 11 cm field size at a dose rate of 0.5 Gy min À1 . A 3-cm polystyrene block was used under the Petri dishes during each irradiation to allow homogeneous back-scattering g-rays. Sourcehalf depth distance (SHD) was initially calculated to obtain a constant dose rate of 0.5 Gy min À1 and monthly adapted from the 60 Co source radioactivity decrease. Control cells were removed from the incubator and placed for the same period of time under the 60 Co source but without radiation treatment. In the combined treatment modality studies, TNFa was added 12 h prior to RT (see Results, 'TNFa enhances radiosensitivity'). For in vivo tumour treatment, the radiation was delivered to the flank of five mice simultaneously in a 12.5 cm Â 12.5 cm field size at 6 Gy fraction À1 at a dose rate of 0.5 Gy min À1 (SHD of 158 cm), twice a week, for a total dose of 30 Gy. A 6-cm thickness lead block with eight circular apertures, 3 cm in diameter, was used so that only the tumours and the underlying normal tissues were exposed to the radiation. Radiation was measured using dosimetry films (RA711P, Agfa, Belgium).
Immediately prior to irradiation, the mice were anaesthetised by intraperitoneal injection of 233 mg g À1 of tribromoethanol dissolved in an ethanol : saline combination (1 : 10, v v À1 ). The anaesthetic was given to all mice, regardless of treatment group, to equalise the effects due to stress.
Clonogenic assay
The colony-forming assay and growth curve analyses were used to assess the sensitivity of the BxPC-3 cells to TNFa. Cultures were trypsinised, washed, and cells were plated in quintuplicate at a density of 100 per 60-mm Petri dishes. TNFa was added at concentrations ranging from 0.3 to 5000 U ml À1 12 h after the cells were plated to allow for cell attachment. Cells were incubated at 371C in a humidified chamber containing 5% CO 2 for 12 days. The colonies were then fixed with a 1 : 3 (v v À1 ) acetic acid : methanol solution and stained with 10% Giemsa (Sigma Chemical Co., St Louis, MO, USA); colonies of more than 50 cells were scored. Plating efficiency was calculated with and without TNFa. The dose -response curves were fitted to a four-parameter logistic model, where the response, R, varies with the dose, D, according to the equation:
where a is the difference between the maximum and minimum response, b is the concentration of drug needed to obtain 50% of the maximal effect, c is a slope factor, and R is the maximal effect. The cytotoxic effect of irradiation on asynchronous, exponentially growing BxC-3 cells was also determined by the colony-forming assay. Before irradiation, cell density was determined using appropriate dilutions (100, 300, 600, and 1600 cells for 0, 2, 4, and 6 Gy, respectively), and five replicates of each dilution were plated in 60-mm Petri dishes. Cells were irradiated as described above, 24 h after plating to allow for cell attachment prior to the administration of radiation. The TNFa-containing medium was given at a concentration of 625 U ml À1 12 h before irradiation. A dose of 625 U ml À1 of TNFa was chosen because colony-forming assays showed that this dose was sufficient to induce only partial (48% survival) cell growth when the cytokine was used alone. Cultures were irradiated when the drug was in the medium and were immediately returned to the incubator after irradiation. Colonies were counted after 14 days. Experimentally derived data points are the mean of three experiments. The multitarget model survival curves were fit to the data using a least-squares regression to the linear-quadratic model, S ¼ S 0 exp (ÀaD 1 ÀbD 1 2 ), where D 1 is the radiation dose, S the surviving fraction, and S 0 a normalising parameter.
Flow cytometry
Cells were plated in 60-mm Petri dishes at a density of 5 Â 10 6 cells dish
À1
. Treatment consisted of TNFa (625 U ml À1 ) alone at 24 h (H24), RT (4 Gy) at H36, or TNFa (625 U ml À1 at H24) þ RT (4 Gy at H36). Cells were collected at 48 and 96 h after cell culture and processed for cell cycle analysis. Cells were harvested by trypsinisation, washed with PBS, and then 1 Â 10 6 cells dish À1 of treatments were fixed in 70% ethanol for 2 min. After removal of ethanol by centrifugation, cells were then stained with a solution containing 40 mg ml À1 propidium iodide (Sigma, St Louis, USA) and 0.1 mg ml À1 RNase A (Roche, Indianapolis, USA). Stained
Radiation enhancement using a bispecific antibody D Azria et al nuclei were analysed for DNA-PI fluorescence using a Becton Dickinson FACScan flow cytometer. Resulting DNA distributions were analysed by the CellQUEST software (Becton Dickinson, Mountain View, CA, USA) for the proportion of cells in sub-G0, G1, S, and G2 -M phases of the cell cycle. In a second series of experiments, cells were treated with TNFa (625 U ml À1 ) alone at H24 and then cultured for 3 days. Medium was then harvested and replaced by RPMI. Cells were stained at different time points up to 21 days and analysed for DNA content on a FACScan as described above.
In vivo model
All the in vivo experiments were performed in compliance with the French guidelines for experimental animal studies (Agreement No. A34220) and fulfil the UKCCCR Guidelines for the welfare of animals in experimental neoplasia.
Mice Athymic 7 -9-week-old female Swiss nude mice (nu/nu, Iffa Credo, l'Arbresle, France) were housed in self-contained filtertop cages (five mice cage À1 ) in a facility controlled for temperature, humidity, and a 12 : 12 h light : dark cycle under sterile conditions. The animals were given autoclaved food and water ad libitum.
Experimental protocols The human pancreatic carcinoma BxPC-3 cells were harvested with 0.25% trypsin solution, washed, and adjusted to 2 Â 10 6 150 ml À1 RPMI-1640 medium without fetal calf serum. Each mouse was injected s.c. in the right flank with 150 ml of the cell suspension. After 35 days, the mice were grouped according to tumour size by measuring tumour diameters with a Vernier caliper to avoid nonhomogeneous groups before beginning treatments. Tumour dimensions were measured twice weekly and volumes (mm On day 35, the mice were assigned to seven different treatment groups (five mice per group) as follows:
Group 1: 0.9% NaCl i.v. injection alone (200 ml injection À1 ) for this control group on days 34, 37, 41, 44, and 48.
Group 2: TNFa at 1 mg i.v. À1 injection alone (in 200 ml 0.9% NaCl injection À1 ) on days 34, 37, 41, 44, and 48. Group 3: BAb at 25 mg i.v.
À1 injection alone (in 200 ml 0.9% NaCl injection À1 ) on days 33, 36, 40, 43, and 47. Group 4: BAb þ TNFa (ratio 25 mg : 1 mg; molar ratio 12.5 : 1) i.v. injection (in 200 ml 0.9% NaCl injection À1 ) on days 33, 36, 40, 43, and 47. BAb -TNFa mixture was prepared 24 h before injection.
Group 5: Local radiation as described above delivered on days 34, 37, 41, 44, and 48 þ 0.9% NaCl i.v. injection (200 ml injection À1 ) 3 h before irradiation.
Group 6: Local radiation as described above delivered on days 34, 37, 41, 44, and 48 þ TNFa i.v. injection administered using the same time -dose schedules as for group 2 with TNFa injections 3 h before irradiation
Group 7: Local radiation þ BAb þ TNFa administered using the same time -dose schedules as for group 4 concerning BAb þ TNFa and group 5 in regard to radiation.
All i.v. injections were performed in the heat dilated tail vein; the day of tumour implantation was day 0. On the basis of the biodistribution studies of TNFa and BAb -TNFa complexes (Robert et al, 1996) , we decided to inject TNFa 3 h prior to RT (group 6) and BAb -TNFa complexes 24 h prior to RT (group 7). The mice were weighed twice a week and routinely observed for signs of toxicity throughout the study particularly digestive toxicity because of the local flank irradiation.
Statistical analyses
The nonparametric Wilcoxon's signed-rank test was used to compare the surviving fraction between the two groups (RT alone and RT þ TNFa). For in vivo experiments, the results were expressed in terms of the time taken for the tumour to reach a volume of 1500 mm 3 . The Kaplan -Meier method was used to estimate the median time taken to reach a tumour volume of at least 1500 mm 3 . Differences among treatment groups were tested by the log-rank test. All statistical tests were two-sided with an a level of 0.05. Data were analysed with software STATA 7.0 (Stata Corporation, College Station, TX, USA).
RESULTS
TNFa inhibits BxPC-3 proliferation
The cytotoxic effects of increasing concentrations of TNFa (0.3 -5000 U ml À1 ) on asynchronous, exponentially growing BxPC-3 cells were determined in colony-forming assays. Cell survival followed a dose -response curve fitted to a four-parameter logistic model as described in Materials and Methods.
Cells were killed by concentrations of TNFa as low as 10 U ml
À1
( Figure 1A ). The LC 50 , defined as concentration of drug that reduced the cell survival rate to 50% of that of the controls, was 625 U ml
. Next, BxPC-3 cells were treated with TNFa (625 U ml À1 ) þ BAb (molar ratio of 100 : 1, 1 : 1, or 1 : 100) and plating efficiencies were compared with that obtained with TNFa alone. No difference in the surviving fraction was observed when BAb was added to TNFa at the same or lower molar ratio. In contrast, when BAb was added in a 100-fold excess, the surviving fraction of cells exposed to 2 Gy was 30% greater than that observed with TNFa alone, probably due to competition between the anti-TNFa arm of the BAb in solution and the TNFa receptor on the cell surface.
TNFa enhances radiosensitivity
Cell survival following irradiation ( Figure 1B ) in aerated medium fit a linear quadratic model as described in Materials and Methods. The surviving fraction at 2 Gy (SF2) was 0.73 and a D 0 (dose of radiation giving 37% survival rate) of 4 Gy when irradiation was used alone. As shown in Figure 2 , TNFa added 12 h before RT (H-12) led to a significant decrease of the surviving fractions as compared with those obtained when TNFa was added at H-1 or H þ 12 (P ¼ 0.02) or when RT was delivered alone. For further experiments using RT with TNFa, we used TNFa at a concentration of 625 U ml À1 added 12 h before RT. In this combination treatment, SF2 and D 0 were 0.29 and 1.2 Gy, respectively. SF2 was 60% lower in combination treatment with a significant test result (Po0.00001). When the data were analysed according to the linear quadratic model, the a and b components were 0.18870.08 and 0.01770.011 Gy À2 , respectively, without TNFa and 0.3970.06 Gy À1 and nearly 0 Gy À2 in combination treatments. These data indicate that treatment with TNFa results in a steeper decline in cell survival due both to a higher initial slope of the dose -response curve and a major decrease of the quadratic parameter. These results show possible additivity between the two treatments, as confirmed by isobologram analysis (Azria et al, 2003b) .
TNFa induces G 1 cell cycle arrest
The effect of TNFa treatment on cell cycle phase distribution in BxPC-3 cell line was evaluated using flow cytometry (Figure 3) . Treatment with 625 U ml À1 TNFa for 24 h induced accumulation of cells in G 1 phase (72.8%) with a significant decrease in the percentage of cells in S phase (20.3%) relative to controls (49.6 and 37.8%, respectively) ( Figure 3A and B). No cells with subdiploid DNA content was observed, consistent with other results on human colorectal cell line LS174T (Azria et al, 2003b) demonstrating that TNFa does not induce apoptosis in these cell lines. After 3 days of treatment, cells were washed and further cultured for 21 days in the absence of the cytokine. We observed a nonreversible G1 cell cycle arrest (nearly 70% at day 21) without any renewal of activity of the S phase as compared to day 3 after TNFa treatment (Table 1) .
At 1 day after RT alone, we observed a cell cycle arrest in the G 2 phase (40%) with a decrease in the percentage of cells in the G0/G1 and S phases as compared with the control (39 vs 50% and 21 vs 38%, respectively). When TNFa was added 12 h before RT, the radiation-induced G 2 /M arrest decreased as compared with RT alone (31 vs 40%, respectively) with a TNFa-induced G 0 /G 1 blockade and a very low S phase ( Figure 3C and D) .
BAb þ TNFa augments in vivo tumour response to radiation
BxPC-3 tumours growing s.c. in the right flank of nude mice were used to test the antitumour activity of TNFa alone or in combination with RT. TNFa was injected i.v. alone or coinjected with the anti-CEA/anti-TNFa BAb (BAb -TNFa mixture was prepared 24 h before injection at a molar ratio of 12.5 : 1). Median pretreatment tumour volumes (day 35) were 128 (6 -135) mm 3 with no statistical difference between the groups. Tumour growth was then measured regularly until tumours were larger than 1500 mm 3 . Radiation alone (group 5), but not TNFa alone (group 2), significantly inhibited tumour progression as compared with the control group (Po0.00001). No difference in growth delay was observed between the control group and groups without RT (groups 2 -4). During the same period of observation, treatment with TNFa slowed tumour growth in irradiated groups, particularly when TNFa was coinjected with BAb. At day 93, when mice in all other groups were killed (tumour 41500 mm 3 ), the median value of the tumour volume was 260 mm 3 for the RT þ BAb þ TNFa group.
The results expressed in terms of the time to reach 1500 mm 3 are shown in Figure 4 . In the control group and the groups treated with TNFa, BAb, or BAb þ TNFa, the median delay for the mice to reach a tumour volume greater than 1500 mm 3 was 62, 62, 65, and 62 days, respectively, with no statistical difference between the groups. In the RT-treated groups, the median delays were 90, 93, and 142 days for the RT alone, the RT þ TNFa, and the RT þ BAb þ TNFa groups, respectively. No statistical difference was observed between the RT and RT þ TNFa groups. However, in the presence of the BAb, the curve for group 7 was shown to be statistically different from the growth curves for tumours treated with RT alone or RT þ TNFa (P ¼ 0.0011).
At the end of all treatments, no significant differences were found in mouse body weight between the seven groups. The mean7s.e.m. were 23.170.47, 22.470.87, 23.670.61, 2470.65, 2470.37, 24.470.41, 23.770 .54 for groups 1, 2, 3, 4, 5, 6, 7, respectively. No diarrhoea was observed in any group, suggesting the absence of digestive toxicity. No significant fluid retention, respiratory distress, or other signs of toxicity were observed in any of the animals during the course of the study. ) added 12 h prior to irradiation showed a surviving fraction at 2 Gy, which was statistically lower (Po0.00001) than when combination treatment was used. When the data were analysed according to the linear quadratic model, the a and b components were, respectively, 0.18870.08 Gy À1 and 0.01770.011 Gy À2 without TNFa and 0.3970.06 Gy À1 and about 0 Gy Figure 2 Effect of TNFa on the radiosensitivity of BxPC-3 cells. The influence of TNFa added 12 h before, 1 h before, or 12 h after RT. Results are expressed in terms of the surviving fraction as described in Materials and Methods. Cells were exposed to TNFa (625 U ml
À1
) and irradiated at the different time points. Control cells were exposed to radiation without TNFa treatment.
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DISCUSSION
Pancreatic carcinoma is the fourth leading cause of cancer deaths. Patient survival of this devastating disease is bleak with less than 5% of patients surviving 5 years after the time of diagnosis (Greenlee et al, 2000) . The current treatment includes a combination of surgery, chemotherapy, and radiation without any major improvement in survival (Azria et al, 2002) . Over 10 years ago, it was hypothesised that TNFa could increase tumour response to radiation through stimulation of the host antitumour immune responses, direct tumour-cell kill, or through the increase in tumour-cell sensitivity to radiation (Sersa et al, 1988; Hallahan et al, 1990; Gridley et al, 1994a, b; Kimura et al, 1999; Azria et al, 2003a) . However, early clinical trials were generally disappointing, with hypotension and vascular leakage frequently being the doselimiting side effects (Chapman et al, 1987; Sherman et al, 1988) . To overcome these limitations, we used a BAb directed against CEA and human TNFa to target this cytokine to the human pancreatic carcinoma cells BxPC-3 treated simultaneously with RT.
In the first part of our study, we demonstrated direct cytotoxicity of TNFa on BxPC-3 cells in culture using a clonogenic assay: TNFa-treated BxPC-3 cells showed reduced plating efficiency (Figure 1) , confirming that TNFa can be tumoristatic or tumoricidal as described for a variety of neoplastic cell types (Hallahan et al, 1990; Manetta et al, 1990; Gridley et al, 1994a; Kimura et al, 1999; Azria et al, 2003a) . In a time-course experiment After 3 days of treatment, cells were washed and further cultured for 21 days in the absence of the cytokine. Cells were fixed and stained with PI for flow cytometry analysis at different time points up to 21 days. DNA histograms were modelled with CellQUEST analysis software and phase percentages for G0/G1, S, and G2/M were determined.
( Figure 2 ), we demonstrated that maximal cell killing increase was obtained when TNFa was added to the cells 12 h before RT as compared with 1 h before and 12 h after RT. These data confirmed those published by Hallahan et al (1990) , who demonstrated that addition of TNFa 4 to 12 h prior to irradiation maximally increases cell killing. We also observed that TNFa induced a G 1 cell cycle arrest and that cell exposure for 24 h to TNFa was sufficient to obtain this effect, which could be considered as irreversible since the G 1 arrest was maintained up to 21 days after elimination of TNFa from the culture medium (Table 1) . This effect can probably be explained by modifications of the expression of cell-cycle-related proteins (ongoing research), as described for other cytokine such as interferon g (Matsuoka et al, 1999; Gooch et al, 2000) , and by the fact that TNFa induces BxPC-3 cycle distribution modification which may render the cells more radiosensitive. In the RT -TNFa combination treatment, we observed a 25% decrease of BxPC-3 cells arrested in the G 2 phase as compared with RT alone, a proportional redistribution in the G 1 phase, and an interrupted synthesis phase. We did not observe any induction of apoptosis in BxPC-3 cells, as previously suggested in another model (Gridley et al, 1994a) and recently described in a human prostate carcinoma cell line (Kimura et al, 1999) . This cell cycle redistribution phenomenon may also explain the decrease in the surviving fraction in the combination treatment presented in the present study ( Figure 1B ). To our knowledge, these results are the first to confirm that TNFa is a biological cell cycle modifier, which is responsible for a cell cycle redistribution in the more radiosensitive (G 1 ) phase rather than in the S phase. Recently, Dormond et al (2002) described that TNFa alone or in combination with IFNg induced a G 1 arrest in endothelial cells (HUVEC), which was associated with reduced levels of cyclin D1 and cdk2, and with increased expression of the cdk inhibitors p16
INK4a , p21 WAF , and p27
Kip1 . In the present study, the in vitro growth-inhibitory effect of TNFa was accompanied by a marked enhancement of the radioresponse of the tumour in vivo, particularly, when TNFa was concentrated in the tumour xenografts thanks to our BAb. In addition to the in vitro cytotoxic effect of TNFa, indirect in vivo mechanisms could be responsible for this synergistic rather than additive effect of the combination . Several studies have demonstrated the antitumour activity of RT þ TNFa, but this treatment was given before the tumours reached a palpable volume, making a comparison with our results difficult (Gridley et al, 1994b (Gridley et al, , 1997 . In mammary carcinoma and sarcoma models, TNFa was shown to significantly increase tumour radiocurability even when TNFa was injected 3 h after RT (Sersa et al, 1988; Nishiguchi et al, 1990 ). Our data demonstrate the interest of targeting TNFa to tumours to improve RT and finally to keep a large differential effect between tumour and normal tissues. Various methods have recently tried to concentrate TNFa into tumour such as Cu2 þ -dextran (Tabata et al, 1999) , TNFa-biotin conjugates (Moro et al, 1997; Gasparri et al, 1999) , or liposomal encapsulated-TNFa (Kim et al, 2001) which are less specific targeting than our BAb and were not tested with concomitant radiotherapy.
Another approach currently in clinical evaluation uses an adenoviral vector that contains radio-inducible DNA sequences from the early growth response gene (EGR1) promoter and cDNA for the gene encoding human TNFa. While avoiding the systemic side effects of TNFa, this method involves injections in or near the tumour, which might be difficult to perform in the case of pelvic or retroperitoneal tumours (Weichselbaum et al, 2002) .
Concerning the immunotargeting strategy, two attractive methods have been recently described. Cooke et al (2002) tested a genetic fusion of human recombinant TNFa with MFE-23, a single-chain Fv antibody fragment directed against CEA. Radiolabelled fusion protein binds both human and mouse TNF receptor 1 in vitro and in vivo and is able to localise effectively in nude mice-bearing human LS174T xenografts with a tumour/tissue ratios of 21 : 1 and 60 : 1 achieved 24 and 48 h after i.v. injection, respectively. The maximum % injected dose (ID) g À1 LS174T tumour (4.33) was obtained 6 h postinjection. At that time, in T380 human colon carcinoma nude mice, our BAb was able to concentrate up to 7.15% ID g À1 of tumour as compared to 2.2% when BAb was injected alone (Robert et al, 1996) . Wüest et al (2002) described a TNFa fusion protein designated TNF-Selectokine, which is a homotrimeric molecule comprised of a singlechain antibody (scFv) targeting molecule, a trimerisation domain and TNFa. Membrane targeting dependent immobilisation of this TNF-Selectokine induced cell death in TNFR1 and TNFR2 dependent manner. The authors constructed, also, a TNFSelectokine prodrug by insertion of a TNFR1 fragment separated from TNF by a protease-sensitive linker in order to restrict TNF activity to the tumour. Both studies suggest interests but are in the early phase of development without any indications of their capacity of radiation enhancement.
The results of our study should be of potential clinical interest. They provide a rational for the combination of TNFa, BAb, and RT in the treatment of adenocarcinoma of the pancreas. One of the advantages of our BAb strategy, namely, the potential decrease of TNFa systemic toxicity, cannot be addressed in our nude mice model, which lacks T cells. The difference between the TNFa þ RT and the BAb þ TNFa þ RT combination treatments will probably be even more evident in an immunocompetent model or in a clinical setting. Such an immunocompetent situation is also needed for the entire expression of TNFa antitumour action, including immunological (production of IL-1 and IFNg, activation of macrophages, and NK cells; Dinarello et al, 1986; Ostensen et al, 1987; Talmadge et al, 1987) and nonimmunological mechanisms such as damage to the tumour vasculature (Gamble et al, 1985; Sato et al, 1986; Cavender et al, 1987; Ruegg et al, 1998) .
In conclusion, we demonstrated that an anti-CEA/anti-TNFa BAb can markedly enhance the radioresponse of pancreatic tumour xenografts in nude mice. Presently, we are testing the antitumour effect of BAb, TNFa, and RT combination in an immunocompetent CEA-transgenic mice transplanted with a syngenic CEA-expressing tumour in which all the effects of the targeted cytokine can be analysed. The next step will be the opening of a phase I clinical study in locally advanced pancreatic cancer. 
